StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Nephroplus (NEPHROPLUS)

Hospitals & Diagnostics · NSE · end-of-day 2026-10-19

₹611.55

Day change

-0.46%

1-year

+29.8%

From 52-week high

-20.1%

Weinstein stage

Stage 1

Minervini template

—

Nephroplus closed at ₹611.55 on 2026-10-19, up 30% over the past year, 20% below its 52-week high. Weinstein's stage analysis reads stage 1 - basing. Over the year its annualised volatility was about 41%, with a largest fall of 20% from a peak.

About Nephroplus

NephroPlus operates dialysis centers and provides kidney-care and related healthcare services through a network of facilities. Its business benefits from increasing prevalence of kidney-related conditions and growing demand for organized dialysis services. Expansion of centers, hospital partnerships and greater healthcare coverage can support growth. Patient volumes, reimbursement rates, operating costs, medical staffing, regulatory requirements and competition remain important factors.

Price, RSI and MACD

6M1Y

Price · +6.7% over the period

RSI (14) · 28.9

MACD (12, 26, 9) · histogram -3.83

Price · +29.8% over the period

RSI (14) · 28.9

MACD (12, 26, 9) · histogram -3.83

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	Debt / equity	Free cash flow	EV / EBITDA	Beta
₹6,136 cr	—	—	—	—	5.50	—	0.07	₹114 cr	24.3	0.69

Quarterly results

Quarter	Sales ₹ cr	Net profit ₹ cr	EPS	EPS YoY	Sales YoY	Net margin
Jun 2026	282	32	3.19	—	—	11.3%
Mar 2026	266	30	3.03	—	—	11.4%
Dec 2025	260	32	3.43	—	—	12.4%

Consolidated · EPS restated onto today's share count after splits and bonuses · net profit as filed.

Minervini SEPA — earnings checks 0 of 0 pass

Check	Result
Latest quarter EPS up 25%+ on a year ago	— Not assessable
EPS growth accelerating over 3 quarters	— Not assessable
Sales up 25%+, or sales growth accelerating	— Not assessable
Annual EPS up 25%+ in each of the last 2 years	— Not assessable
Net margin above the same quarter last year	— Not assessable

Investor methods

Method	Checks	Verdict
Turtle	✗ Close above the prior 55-session high · 781.50 ✗ Close above the prior 20-session high · 762.10 ✗ Close below the prior 20-session low · 601.05 Donchian channel breakout - the Turtle traders' entry.	No signal
Weinstein	Stan Weinstein's stage analysis on the 30-week moving average.	Stage 1 - basing
Graham	Needs positive earnings and book value.	Not assessable

Each method's own rules applied to this stock - information, not a buy or sell signal. All were tested on 2024-26 data; only the Minervini trend template showed a consistent edge.

Hospitals & Diagnostics sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
NEPHROPLUS this stock	-17.7	-2.7	+6.7	—	—	—	—	5.50	—	—	—	0.07	24.3	6,136	—	—	—	0.69
SAKAR	-21.8	+2.7	+51.5	+162.7	+158.4	+464.3	57.0	6.33	10.0	12.9	—	0.17	30.8	2,054	272	36	16.2	0.69
KOVAI	-5.6	-0.9	+7.0	+128.0	+118.8	+256.0	25.5	4.87	19.4	—	—	—	—	6,429	—	—	234.2	—
AHCL	+17.8	+79.8	+86.2	+112.4	—	—	11.1	6.23	47.4	—	—	0.19	30.7	1,434	—	—	2.4	0.44
VIJAYA	-12.2	+2.5	+33.7	+37.9	+134.0	+143.8	75.1	14.71	19.7	30.3	—	0.00	39.6	14,078	857	188	18.2	0.54
ENTERO	-13.2	+26.4	+18.2	+35.9	—	—	52.2	3.88	6.7	10.7	—	0.34	26.4	6,545	7,128	168	28.8	0.36
AMANTA	-13.3	-0.0	+21.9	+34.8	—	—	39.6	2.57	—	—	—	1.06	—	—	291	15	4.2	0.73
YATHARTH	-14.8	+14.4	+30.6	+19.8	+147.7	—	51.6	5.18	10.0	12.4	—	0.14	30.2	9,356	1,334	174	18.8	0.88
LALPATHLAB	-2.8	+8.9	+30.0	+18.6	+47.0	-0.3	56.8	12.32	21.6	29.1	—	0.00	36.2	30,900	2,891	546	32.5	0.41
THYROCARE	-15.3	-15.2	+19.9	+13.6	+151.4	+22.7	42.6	12.80	28.8	37.8	—	0.00	28.2	7,497	876	176	11.1	0.47
STARHEALTH	-0.9	-6.7	+7.0	+7.6	-8.9	—	35.7	3.15	8.9	—	—	—	—	31,904	—	—	15.3	0.41

A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Hospitals & Diagnostics stocks of a similar size

Kovai Medical Center & Hospital Limited Entero Healthcare Solutions Limited Medplus Health Thyrocare Technologies Sanofi Consumer Healthcare India Limited Zota Health Care Limited Hcg Yatharth

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-19, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact